CA2923269C - Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof - Google Patents
Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof Download PDFInfo
- Publication number
- CA2923269C CA2923269C CA2923269A CA2923269A CA2923269C CA 2923269 C CA2923269 C CA 2923269C CA 2923269 A CA2923269 A CA 2923269A CA 2923269 A CA2923269 A CA 2923269A CA 2923269 C CA2923269 C CA 2923269C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- mixture
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310174990 | 2013-05-13 | ||
| CN201310174990.6 | 2013-05-13 | ||
| PCT/CN2014/076447 WO2014183555A1 (zh) | 2013-05-13 | 2014-04-29 | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2923269A1 CA2923269A1 (en) | 2014-11-20 |
| CA2923269C true CA2923269C (en) | 2023-02-14 |
Family
ID=51897690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2923269A Active CA2923269C (en) | 2013-05-13 | 2014-04-29 | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9637484B2 (https=) |
| EP (1) | EP2998296B1 (https=) |
| JP (1) | JP6440690B2 (https=) |
| KR (1) | KR102240158B1 (https=) |
| CN (1) | CN104470898B (https=) |
| AU (1) | AU2014267974B2 (https=) |
| BR (1) | BR112015027303B1 (https=) |
| CA (1) | CA2923269C (https=) |
| CY (1) | CY1120515T1 (https=) |
| DK (1) | DK2998296T3 (https=) |
| ES (1) | ES2668721T3 (https=) |
| HU (1) | HUE037512T2 (https=) |
| LT (1) | LT2998296T (https=) |
| MX (1) | MX362747B (https=) |
| NO (1) | NO2998296T3 (https=) |
| PL (1) | PL2998296T3 (https=) |
| PT (1) | PT2998296T (https=) |
| TR (1) | TR201807104T4 (https=) |
| TW (1) | TWI654172B (https=) |
| WO (1) | WO2014183555A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3305768T (lt) * | 2015-05-27 | 2020-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | Šlapimo rūgšties natrio druskos transporterio inhibitorius ir jo kristalinė forma |
| JP6740354B2 (ja) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
| WO2017097182A1 (zh) * | 2015-12-07 | 2017-06-15 | 成都海创药业有限公司 | 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途 |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108201529B (zh) * | 2016-12-16 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 |
| EP3712148B1 (en) * | 2017-11-23 | 2021-07-07 | Medshine Discovery Inc. | Crystal forms of a urat1 inhibitor, and preparation methods therefor |
| CN110452168B (zh) * | 2018-05-07 | 2022-03-15 | 中国医学科学院药物研究所 | N-苯基-n-喹啉羧酸类化合物及其制法和药物用途 |
| CN110467571B (zh) * | 2018-05-11 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种制备环烷基甲酸类衍生物或其可药用盐的方法 |
| CN112512526B (zh) * | 2018-11-02 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN114315715B (zh) * | 2020-09-29 | 2024-02-20 | 杭州中美华东制药有限公司 | 一类urat1抑制剂及其制备方法与应用 |
| AU2023285760B2 (en) * | 2021-05-19 | 2025-07-10 | Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd. | Quinoline Mercaptoacetate Sulfonamide Derivative, Intermediate, Pharmaceutical Derivative Or Formulation, And Preparation Method And Use Therefor |
| CN118439998A (zh) * | 2021-05-19 | 2024-08-06 | 江苏正大清江制药有限公司 | 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| TW200716132A (en) | 2005-05-03 | 2007-05-01 | Smithkline Beecham Corp | Novel chemical compounds |
| US7776857B2 (en) | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2008153129A1 (ja) | 2007-06-14 | 2008-12-18 | Teijin Pharma Limited | 尿酸値低下剤 |
| ME01294B (me) | 2007-11-27 | 2013-06-20 | Ardea Biosciences Inc | Nova jedinjenja i kompozicije i metode upotrebe |
| WO2010044403A1 (ja) | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | ５員環ヘテロアリール誘導体及びその医薬用途 |
| CN102573462B (zh) | 2009-10-13 | 2014-04-16 | 维尔斯达医疗公司 | 用于降低尿酸的3位取代的化合物 |
| AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| BR112012032193A2 (pt) * | 2010-06-16 | 2019-09-24 | Ardea Biosciences Inc | composto, composiçoes e métodos de uso de feniltioacetato |
-
2014
- 2014-04-29 LT LTEP14798044.5T patent/LT2998296T/lt unknown
- 2014-04-29 JP JP2016513214A patent/JP6440690B2/ja active Active
- 2014-04-29 EP EP14798044.5A patent/EP2998296B1/en active Active
- 2014-04-29 TR TR2018/07104T patent/TR201807104T4/tr unknown
- 2014-04-29 US US14/889,563 patent/US9637484B2/en active Active
- 2014-04-29 WO PCT/CN2014/076447 patent/WO2014183555A1/zh not_active Ceased
- 2014-04-29 PL PL14798044T patent/PL2998296T3/pl unknown
- 2014-04-29 KR KR1020157034797A patent/KR102240158B1/ko active Active
- 2014-04-29 CA CA2923269A patent/CA2923269C/en active Active
- 2014-04-29 NO NO14798044A patent/NO2998296T3/no unknown
- 2014-04-29 PT PT147980445T patent/PT2998296T/pt unknown
- 2014-04-29 ES ES14798044.5T patent/ES2668721T3/es active Active
- 2014-04-29 BR BR112015027303-3A patent/BR112015027303B1/pt active IP Right Grant
- 2014-04-29 DK DK14798044.5T patent/DK2998296T3/en active
- 2014-04-29 MX MX2015015393A patent/MX362747B/es active IP Right Grant
- 2014-04-29 CN CN201480001853.5A patent/CN104470898B/zh active Active
- 2014-04-29 HU HUE14798044A patent/HUE037512T2/hu unknown
- 2014-04-29 AU AU2014267974A patent/AU2014267974B2/en active Active
- 2014-05-09 TW TW103116499A patent/TWI654172B/zh active
-
2018
- 2018-06-13 CY CY20181100621T patent/CY1120515T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9637484B2 (en) | 2017-05-02 |
| CY1120515T1 (el) | 2019-07-10 |
| MX362747B (es) | 2019-02-05 |
| JP6440690B2 (ja) | 2018-12-19 |
| ES2668721T3 (es) | 2018-05-21 |
| AU2014267974B2 (en) | 2018-08-30 |
| LT2998296T (lt) | 2018-08-10 |
| US20160108035A1 (en) | 2016-04-21 |
| HK1205118A1 (zh) | 2015-12-11 |
| CN104470898A (zh) | 2015-03-25 |
| DK2998296T3 (en) | 2018-05-22 |
| MX2015015393A (es) | 2016-03-15 |
| PL2998296T3 (pl) | 2018-12-31 |
| HUE037512T2 (hu) | 2018-08-28 |
| BR112015027303A2 (https=) | 2017-09-05 |
| PT2998296T (pt) | 2018-06-15 |
| BR112015027303B1 (pt) | 2023-04-25 |
| EP2998296B1 (en) | 2018-03-14 |
| EP2998296A1 (en) | 2016-03-23 |
| CA2923269A1 (en) | 2014-11-20 |
| KR20160006207A (ko) | 2016-01-18 |
| AU2014267974A1 (en) | 2015-11-12 |
| KR102240158B1 (ko) | 2021-04-15 |
| CN104470898B (zh) | 2016-04-06 |
| JP2016520072A (ja) | 2016-07-11 |
| TWI654172B (zh) | 2019-03-21 |
| WO2014183555A1 (zh) | 2014-11-20 |
| NO2998296T3 (https=) | 2018-08-11 |
| EP2998296A4 (en) | 2016-12-14 |
| TR201807104T4 (tr) | 2018-06-21 |
| TW201443010A (zh) | 2014-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2923269C (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| JP7675777B2 (ja) | 免疫調節剤としての複素環式化合物 | |
| KR101819199B1 (ko) | 안드로겐 수용체 조절제 및 이의 용도 | |
| JP5191497B2 (ja) | Ｓ１ｐ受容体調節化合物およびその使用 | |
| CN105814045B (zh) | 作为tnf活性调节剂的咪唑并吡啶衍生物 | |
| CN102264707B (zh) | 双环型杂环化合物 | |
| WO2022028506A1 (zh) | Sos1抑制剂、包含其的药物组合物及其用途 | |
| EP3172212B1 (en) | Aldosterone synthase inhibitors | |
| JP2020203945A (ja) | それに関連する障害の治療または予防に有用なβ−３アドレナリン受容体調節剤 | |
| JP7369139B2 (ja) | Ｐｉ３キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体 | |
| CN107787319A (zh) | 作为tnf活性的调节剂的吲唑衍生物 | |
| CN104411696A (zh) | 环己烷-1,2′-萘-1′,2″-咪唑化合物及其作为bace抑制剂的用途 | |
| JP7814359B2 (ja) | 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用 | |
| CN103130791B (zh) | 一种新型苯甲酰胺类化合物 | |
| AU2016208310B2 (en) | Androgen receptor modulators and uses thereof | |
| JP2024539222A (ja) | Ｓａｒｍ１調節物質、その調製、及び使用 | |
| JP2025503082A (ja) | カテプシンｋ阻害剤及びその製造方法並びにその応用 | |
| JP2025500892A (ja) | 選択的ｐｈｄ１阻害剤化合物、組成物、及び使用方法 | |
| HK1205118B (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| HK1232870A1 (en) | Aldosterone synthase inhibitors | |
| HK1232870B (en) | Aldosterone synthase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190402 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250325 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250325 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260324 |